Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma

Blood (2019) 134 (Supplement_1): 3182.

https://doi.org/10.1182/blood-2019-128749

Published: 2019

Journal Articles

A Single Institution Comparison of Treatment Outcomes of Adolescent and Young Adult (AYA) Patients with Acute Myeloid Leukemia (AML) Treated in Pediatric and Adult Settings

Vaibhav Agrawal, MD MBA, Jordyn Griffin, MD, Andrew O'Brien, MD, Robert P. Nelson, Jr., MD, Jodi L. Skiles, MD, Heiko Konig, MD PhD

Blood (2018) 132 (Supplement 1): 5859.

https://doi.org/10.1182/blood-2018-99-114189

Published: 2018

Journal Articles

Retrospective Outcomes of Prolonged-Duration Calcineurin Inhibitor Immunosuppression in Severe Aplastic Anemia

Steven D. Green, MD, Joyatee M. Sarker, PhD, Erica B. Bernhardt, MD, Muhammad Khawaja, MBBS,MPH, Robert P. Nelson, Jr., MD

Blood (2017) 130 (Supplement 1): 1186.

https://doi.org/10.1182/blood.V130.Suppl_1.1186.1186

Published: 2017

Journal Articles

Minimal Intensity Fludarabine/Cyclophosphamide Versus Myeloablative Thiotepa/Cyclophosphamide Followed By Allogeneic Hematopoetic Stem Cell Transplantation (HSCT) for the Treatment of Acute Myeloid Leukemia (AML)— a Retrospective Single Institution Experience

Nabin Khanal, MBBS, Brian E Johnson, MD, H. Scott Boswell, MD, Heiko Konig, MDPhD, Susan M Perkins, PhD, Robert P. Nelson, Jr., MD

Blood (2017) 130 (Supplement 1): 5471.

https://doi.org/10.1182/blood.V130.Suppl_1.5471.5471

Published: 2017

Journal Articles

Marrow Environment Post-Transplant Day (+) 7-9 Following Cyclophosphamide and Fludarabine Minimal Intensity Allotransplantation

Brian Myre, MD, Magdalena Czader, MD PhD, Robert P. Nelson, MD

Blood (2014) 124 (21): 5851.

https://doi.org/10.1182/blood.V124.21.5851.5851

Published: 2014

Journal Articles

Aplastic Anemia: A Retrospective Review of Outcomes after Prolonged-Duration Calcineurin Inhibitor-Based Immunosuppression

Erica B Bernhardt, MD, Muhammad Rizwan Khawaja, MD, Robert P. Nelson, MD

Blood (2014) 124 (21): 5148.

https://doi.org/10.1182/blood.V124.21.5148.5148

Published: 2014

Journal Articles

Immunological and Hematological Findings Associated with Thymic Epithelial Neoplasms

Muhammad Rizwan Khawaja, MD, Nicholas J Miller, BS, Patrick J Loehrer, Sr, MD, Robert P. Nelson, Jr, MD

Blood (2010) 116 (21): 1742.

https://doi.org/10.1182/blood.V116.21.1742.1742

Published: 2010

Journal Articles

The Outcome of the Combination of Tacrolimus, Sirolimus, and ATG for GvHD Prophylaxis on Allogeneic Stem Cell Transplantation From Matched Unrelated Donors

Yaser Homsi, MD, Dareen Alwan, MD, Patrick Kiel, PharmD, Lindsay Rosenbeck, PharnD, Srivastava Shivani, MD, Jennifer E. Schwartz, MD, FRCP(C), Robert P. Nelson, Jr., MD, Rafat Abonour, MD, Michael Robertson, MD, Sherif Farag, MD, PhD, FRACP, FRCPA

Blood (2010) 116 (21): 2345.

https://doi.org/10.1182/blood.V116.21.2345.2345

Published: 2010

Journal Articles

Phase I Trial of High-Dose Clofarabine and Busulfan as a Myeloablative Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia.

Sherif Farag, MD, PhD, Lisa L Wood, RN, Jennifer E. Schwartz, MD, FRCP(C), Shivani Srivastava, MD, Robert P. Nelson, Jr., MD, Michael Robertson, MD, Rafat Abonour, MD, Hamid Sayar, MD, Larry D. Cripe, MD

Blood (2009) 114 (22): 198.

https://doi.org/10.1182/blood.V114.22.198.198

Published: 2009

Journal Articles

Infusion of Large Number of Circulating Myeloma Cells Does Not Influence the Survival of Patients Undergoing Autologous Stem Cell Transplantation.

Rafat Abonour, Hayley Knollman, Attaya Suvannasankha, MD, Menggang Yu, Rebecca Britton, Shivani Srivastava, MD, Robert P. Nelson, Jr., MD, Jennifer E. Schwartz, MD, FRCP(C), Michael Robertson, MD, Kenneth Cornetta, MD, Sherif Farag, MBBS, PhD

Blood (2009) 114 (22): 1224.

https://doi.org/10.1182/blood.V114.22.1224.1224

Published: 2009

Journal Articles

A Phase I Trial of High-Dose Clofarabine, Etoposide, and Cyclophosphamide: A Novel Preparative Regimen Prior to Autologous Peripheral Blood Stem Cell (PBSC) Transplantation in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma.

Sherif Farag, MD, PhD, Lisa L Wood, RN, Shivani Srivastava, MD, Robert P. Nelson, Jr., MD, Jennifer E. Schwartz, MD, FRCP(C), Elizabeth Cox, Rafat Abonour, MD, Michael Robertson, MD,

Blood (2009) 114 (22): 3402.

https://doi.org/10.1182/blood.V114.22.3402.3402

Published: 2009

Journal Articles

T Regulatory Cells in Graft-Versus-Host Disease of the Skin

Jose Azar, MD, Steven Billings, MD, Jennifer E. Schwartz, MD, FRCP(C), Yunlong Liu, Menggang Yu, Robert P. Nelson

Blood (2008) 112 (11): 4354.

https://doi.org/10.1182/blood.V112.11.4354.4354

Published: 2008

Journal Articles

Expression of Hypoxia-Inducible Factor (HIF) Is An Independent Favorable Prognostic Factor in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP

Andrew M. Evens, DO, MS, Laurie H. Sehn, MD, MPH, Pedro Farinha, MD, Paul T Schumacker, PhD, Adekunle Raji, MS, Yi Lu, MD, Beverly P. Nelson, MD, Randy D. Gascoyne, MD, Leo I. Gordon, MD

Blood (2008) 112 (11): 479.

https://doi.org/10.1182/blood.V112.11.479.479

Published: 2008

Journal Articles

Outcomes and a New Prognostic Model in Posttransplantation Lymphoproliferative Disorders (PTLD): Intent-to-Treat (ITT) Analysis of 81 Patients in the Post-Rituximab Era.

Andrew M. Evens, DO, MS, Kevin A. David, MD, Irene Helenowski, PhD, Sheetal M. Kircher, MD, Lauren Mauro, MD, Alla Gimelfarb, MD, Koen Van Besien, MD, Elise Hattersley, MD, Beverly P Nelson, MD, Jayesh Mehta, MD, Leo I. Gordon, MD, Jamile M. Shammo, MD, FASCP, Scott E. Smith, MD, PhD, Sonali Smith, MD

Blood (2008) 112 (11): 1776.

https://doi.org/10.1182/blood.V112.11.1776.1776

Published: 2008

Journal Articles

Hypoxia-Inducible Factor-Alpha (HIF-α) Activation in Non-Hodgkin’s Lymphoma (NHL): Relationship to the Thioredoxin Family and Correlation with Survival by Tissue Microarray (TMA).

Andrew M. Evens, DO, MS, Paul T. Schumacker, PhD, Irene B. Helenowski, MS, Amar Singh, PhD, Danijela Dokic, MD, Anjeni Keswani, MD, Elizabeth Kordeluk, BS, Adekunle Raji, MS, Jane N. Winter, MD, Borko D. Jovanovic, PhD, Arne Holmgren, MD, PhD, Beverly P. Nelson, MD, Leo I. Gordon, MD

Blood (2007) 110 (11): 3587.

https://doi.org/10.1182/blood.V110.11.3587.3587

Published: 2007

Journal Articles

Cyclosporine Versus Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis after Matched Related and Unrelated Minimal Intensity Allotransplantation.

Robert P. Nelson, Jr., MD, Jennifer E. Schwartz, M.D., Menggang Yu, Ph.D., Michael Robertson, M.D., Paul R. Haut, M.D., Lisa L. Wood, R.N., Elizabeth A. Cox, Kenneth Cornetta, M.D., Rafat Abonour, M.D.

Blood (2007) 110 (11): 5014.

https://doi.org/10.1182/blood.V110.11.5014.5014

Published: 2007

Journal Articles

T-cell non-Hodgkin lymphoma

Mujahid A. Rizvi, Andrew M. Evens, Martin S. Tallman, Beverly P. Nelson, Steven T. Rosen

Blood (2006) 107 (4): 1255–1264.

https://doi.org/10.1182/blood-2005-03-1306

Published: 2006

Journal Articles

IgMs produced by two acquired immune deficiency syndrome lymphoma cell lines: Ig binding specificity and VH-gene putative somatic mutation analysis [published erratum appears in Blood 1994 Aug 1;84(3):995]

VL Ng, MH Hurt, CL Fein, F Khayam-Bashi, J Marsh, WM Nunes, LW McPhaul, E Feigal, P Nelson, BG Herndier

Blood (1994) 83 (4): 1067–1078.

https://doi.org/10.1182/blood.V83.4.1067.1067

Published: 1994

Journal Articles

Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia

PC Cogswell, R Morgan, M Dunn, A Neubauer, P Nelson, NK Poland-Johnston, AA Sandberg, E Liu

Blood (1989) 74 (8): 2629–2633.

https://doi.org/10.1182/blood.V74.8.2629.2629

Published: 1989

NARROW

CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma

A Single Institution Comparison of Treatment Outcomes of Adolescent and Young Adult (AYA) Patients with Acute Myeloid Leukemia (AML) Treated in Pediatric and Adult Settings

Retrospective Outcomes of Prolonged-Duration Calcineurin Inhibitor Immunosuppression in Severe Aplastic Anemia

Minimal Intensity Fludarabine/Cyclophosphamide Versus Myeloablative Thiotepa/Cyclophosphamide Followed By Allogeneic Hematopoetic Stem Cell Transplantation (HSCT) for the Treatment of Acute Myeloid Leukemia (AML)— a Retrospective Single Institution Experience

Marrow Environment Post-Transplant Day (+) 7-9 Following Cyclophosphamide and Fludarabine Minimal Intensity Allotransplantation

Aplastic Anemia: A Retrospective Review of Outcomes after Prolonged-Duration Calcineurin Inhibitor-Based Immunosuppression

Immunological and Hematological Findings Associated with Thymic Epithelial Neoplasms

The Outcome of the Combination of Tacrolimus, Sirolimus, and ATG for GvHD Prophylaxis on Allogeneic Stem Cell Transplantation From Matched Unrelated Donors

Phase I Trial of High-Dose Clofarabine and Busulfan as a Myeloablative Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia.

Infusion of Large Number of Circulating Myeloma Cells Does Not Influence the Survival of Patients Undergoing Autologous Stem Cell Transplantation.

A Phase I Trial of High-Dose Clofarabine, Etoposide, and Cyclophosphamide: A Novel Preparative Regimen Prior to Autologous Peripheral Blood Stem Cell (PBSC) Transplantation in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma.

T Regulatory Cells in Graft-Versus-Host Disease of the Skin

Expression of Hypoxia-Inducible Factor (HIF) Is An Independent Favorable Prognostic Factor in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP

Outcomes and a New Prognostic Model in Posttransplantation Lymphoproliferative Disorders (PTLD): Intent-to-Treat (ITT) Analysis of 81 Patients in the Post-Rituximab Era.

Hypoxia-Inducible Factor-Alpha (HIF-α) Activation in Non-Hodgkin’s Lymphoma (NHL): Relationship to the Thioredoxin Family and Correlation with Survival by Tissue Microarray (TMA).

Cyclosporine Versus Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis after Matched Related and Unrelated Minimal Intensity Allotransplantation.

T-cell non-Hodgkin lymphoma

IgMs produced by two acquired immune deficiency syndrome lymphoma cell lines: Ig binding specificity and VH-gene putative somatic mutation analysis [published erratum appears in Blood 1994 Aug 1;84(3):995]

Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only